JPRN-jRCTb032200148
Active, not recruiting
未知
Multicenter clinical study on the efficacy and safety with extensive and repeated injections of cultured (human) autologous hair follicle dermal sheath cup cells on male and female pattern hair loss
Harada Kazutoshi0 sites36 target enrollmentOctober 13, 2020
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Harada Kazutoshi
- Enrollment
- 36
- Status
- Active, not recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\. Male or female of 20 year old or more with in good health having pattern hair loss involving the vertex area of the scalp.
- •2\. Male subjects with pattern hair loss characterized as type III vertex to type VI on the Norwood Scale, or equivalent type. Female subjects with pattern hair loss characterized as type 3 to type 6 of the Shiseido Scale.
- •3\. Subjects with willingness to provide written informed consent for participation in the study, to attend all study visits and to complete all procedures required by this protocol.
- •4\. Subjects with willingness to forego the use quasi drug or medical products for hair growth throughout the course of the study.
Exclusion Criteria
- •1\. Use of any product (medication or otherwise) which interferes with the hair growth cycle.
- •2\. Any systemic medical treatment or quasi drug for hair growth within six months prior to obtaining the Informed Consent. Or those who underwent hair loss therapies by LED and/or low power output of raiser radiation within six months prior to obtaining the Informed Consent.
- •3\. Presence of any medical condition that influences the hair growth cycle.
- •4\. Infection with viruses such as HBV, HCV, HIV, adult T\-cell leukemia, parvovirus or VDS has been confirmed by virological examination and syphilis testing carried out at the time of the screening.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Completed
Not Applicable
Multicentre clinical study of the efficacy and safety of INHaled INSulin aerosol in the treatment of type 2 diabetesType 2 diabetesNutritional, Metabolic, EndocrineDiabetesISRCTN81772352Chuangxinhui Biotech Venture Capital Co., Ltd (China)252
Active, not recruiting
Not Applicable
A study conducted at several study sites with a human growth hormone in a liquid form and a concentration of 3.3. mg/mL that is produced by using genetic engineering techniques, to find out more about how efficacious it works and how safe its use is in pre-pubertal children of small stature who’s bodies do not produce sufficient amounts of own growth hormone.Small stature secondary to growth hormone insufficiency deficiencyTherapeutic area: Diseases [C] - Hormonal diseases [C19]EUCTR2015-002802-34-Outside-EU/EEASandoz SAS100
Active, not recruiting
Not Applicable
A Multicenter Study Evaluating the Efficacy and Safety of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Headache Prophylaxis in Migraine Patients with 15 or More Headache Days per 4-Week Period in a 24-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase Followed by a 32-Week Open-Label Extension PhaseEUCTR2005-004637-17-DEALLERGAN LTD650
Active, not recruiting
Phase 1
A Multicenter Study Evaluating the Efficacy and Safety of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex as Headache Prophylaxis in Migraine Patients with 15 or More Headache Days per 4-Week Period in a 24-Week, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Phase Followed by a 32-Week Open-Label Extension PhaseEUCTR2005-004637-17-GBALLERGAN LTD650
Completed
Not Applicable
A clinical multicenter study on efficacy and safety of C1-inhibitor concentrate for clinical amniotic fluid embolismJPRN-UMIN000015686Obstetrics and Gynecology, Hamamatsu University School of Medicine.30